{{author}}{{author}}{{($index > metadata.AuthorsAndEtalArray.length-1) ? ',' : '.'}}

Chris Harding, Thomas Chadwick, Tara Homer, Jan Lecouturier, Helen Mossop, Sonya Carnell, Will King, Alaa Abouhajar, Luke Vale, Gillian Watson, Rebecca Forbes, Stephanie Currer, Robert Pickard, Ian Eardley, Ian Pearce, Nikesh Thiruchelvam, Karen Guerrero, Katherine Walton, Zahid Hussain, Henry Lazarowicz & Ased Ali.

Chris Harding ^1,2,*, Thomas Chadwick ³, Tara Homer ³, Jan Lecouturier ³, Helen Mossop ³, Sonya Carnell ⁴, Will King ³, Alaa Abouhajar ⁴, Luke Vale ³, Gillian Watson ⁴, Rebecca Forbes ⁴, Stephanie Currer ⁴, Robert Pickard ^5,†, Ian Eardley ⁶, Ian Pearce ⁷, Nikesh Thiruchelvam ⁸, Karen Guerrero ⁹, Katherine Walton ¹⁰, Zahid Hussain ¹¹, Henry Lazarowicz ¹², Ased Ali ¹³

¹ Department of Urology, Freeman Hospital, Newcastle upon Tyne, UK
² Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
³ Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK
⁴ Newcastle Clinical Trials Unit, Newcastle University, Newcastle upon Tyne, UK
⁵ Institute of Cellular Medicine, The Medical School, Newcastle upon Tyne, UK
⁶ Leeds Teaching Hospitals NHS Trust, Leeds, UK
⁷ Manchester University NHS Foundation Trust, Manchester, UK
⁸ Addenbrooke’s Hospital, Cambridge, UK
⁹ Queen Elizabeth University Hospital, Glasgow, UK
¹⁰ Department of Microbiology, Freeman Hospital, Newcastle upon Tyne, UK
¹¹ The Royal Oldham Hospital, Oldham, UK
¹² Liverpool University Hospitals NHS Foundation Trust, formerly The Royal Liverpool University Hospital, Liverpool, UK
¹³ Urology Department, Pinderfields Hospital, Wakefield, UK
^* Corresponding author Email: C.Harding@nhs.net

^† In memoriam

In memoriam

Declared competing interests of authors: Chris Harding reports personal fees from Astellas Pharma (Tokyo, Japan), Medtronic plc (Dublin, Ireland), Allergan Ltd (Dublin, Ireland), GlaxoSmithKline plc (Brentford, UK), Teleflex Medical Inc. (Temecula, CA, USA) and grants from Medtronic plc, the National Institute for Health and Care Research (NIHR) Health Technology Assessment (HTA) programme (HTA 15/40/05) and The Urology Foundation (London, UK) outside the submitted work. Karen Guerrero reports grants from the NIHR HTA programme (HTA 16/82/01 and HTA 15/150/05) and the NIHR Health and Social Care Delivery Research (HSDR) programme (HSDR 14/04/02), and a Contura International Ltd (London, UK) Departmental Education Grant to support national training courses to her department. Luke Vale reports being co-ordinating editor of Cochrane Incontinence (from 2016) and being a member of NIHR HTA, Clinical Evaluation and Trials Panel from 2015 to 2018. Thomas Chadwick reports grants from the NIHR HTA programme (HTA 16/154/01, HTA 15/130/94 and HTA 11/72/01) during the conduct of the study.